Andere talen Ayala Pharmaceuticals, Inc.

Aandelen

ADXS

US0076244062

Vertraagde tijd OTC Markets Andere beurzen 19:35:48 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,665 ^USD	+19,82%		+16,26%	-0,30%

16/04	Ayala Pharmaceuticals, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
16/04	Ayala Pharmaceuticals, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
North American Morning Briefing : Focus Turns to -2-	04/04
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	03/04
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	03/04
North American Morning Briefing : Stocks Set for -2-	28/03
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	26/03
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25/03
North American Morning Briefing : Fed's Preferred -2-	29/02
North American Morning Briefing : Nvidia Ignites -2-	22/02
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20/02
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	20/02
Sector Update: Health Care Stocks Gain Late Afternoon	06/02
Top Midday Gainers	06/02
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	06/02
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	06/02
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	06/02
North American Morning Briefing : Stock Futures -2-	27/11
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ayala Pharmaceuticals, Inc.

Aandelen

ADXS

US0076244062

Andere talen

Filters